We hope you enjoy reading our latest newsletter, please reach out if you would like to know more about the impressive work we are doing at entX.
Bryn Jones
Managing Director
We’re excited to unveil our new brand dedicated to Nuclear Medicine, IsoMedica.
IsoMedica focuses on developing process technology to recover valuable isotopes from low-level radioactive waste streams. These isotopes are crucial for producing precursor materials used in cutting-edge cancer therapy treatments. The benefit for Australian and other global cancer therapy markets is breaking the reliance on existing supply chains in countries with increasing stability arising from recent geopolitical issues. Creating this sovereign supply chain will benefit availability and cost of future cancer treatment.
entX Limited has entered into a Heads of Agreement with DGA Energy Solutions Australia Pty Limited (DGA), to divest a 49% equity stake in entX Limestone Coast Hydrogen Project (LCH2 Project), a project planning to produce green hydrogen for Australia’s major tissue manufacturer Kimberly-Clark Australia.
Read more about our new agreement with DGA and view the new 3D renders of the proposed Kimberly-Clark Australia Green Hydrogen Hub in Millicent.
We recently interviewed our General Manager of Hydrogen and Clean Fuels, Glenn Toogood to share his inspiring journey from a small town in Victoria to leading innovative projects in the energy sector. Learn how Glenn’s career path led him to entX and the exciting projects he’s spearheading in the field of green hydrogen developments.
entX Limited held its Annual General Meeting (AGM) on Thursday, 23rd May, 2024. Thank you to all of our shareholders and stakeholders for their participation and support. Download the results of the AGM through the link below.
